This new geographic expansion aligns with CST's commitment to providing researchers direct access to the scientists that develop, characterize, and validate CST antibodies.
Danvers, MA (PRWEB) September 05, 2017
Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced changes to part of its European operations. On January 1st, 2018, CST will now deal directly with its customers in Germany and Austria.
These are key markets for CST. This investment creates a local presence that will provide German and Austrian scientists with direct, efficient access to CST’s high-quality reagents, industry-leading technical support, and services. The decision to go direct allows CST to offer an even higher level of collaboration and personalized services and will help scientists in these regions accelerate their research.
Michael J. Comb, Ph.D., Cell Signaling Technology President and CEO said that this new geographic expansion aligns with CST's commitment to providing researchers direct access to the scientists who develop, characterize, and validate CST antibodies.
Customer satisfaction is CST's highest priority. CST is partnering with its long-term business partner, New England Biolabs GmbH, to ensure a smooth transition through the end of this year. CST will take direct orders effective January 1st, 2018.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing the world’s highest quality, innovative research and diagnostic products to accelerate biological understanding and enable personalized medicine. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Cell Signaling Technology and CST are trademarks of Cell Signaling Technology, Inc.
CST Media Contact:
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Director of Marketing Communications